The results showed that SM preparations group was significantly more effective in lowering CRP, TNF-a, and IL-6 in patients with DKD than in the control group (CRP: MD =-4.47, 95% CI [-6.12, −2.82], I2= 95%, P < 0.00001; TNF-a: MD = −13.27, 95% CI [-15.83, -10.71], I2= 96%, P < 0.00001; IL-6: MD =-11.38, 95% CI [-15.94, -6.82], I2= 97%, P < 0.00001). This evidence concerns the gene CRP and diabetic kidney disease.